Accueil   Diary - News   All news ERYTECH reports positive top-line Phase III results from clinical study with GRASPA®

ERYTECH reports positive top-line Phase III results from clinical study with GRASPA®

ERYTECH (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia.

 

Read the press release

ERYTECH PHARMA